Equity Overview
Price & Market Data
Price: $34.38
Daily Change: +$1.86 / 5.41%
Range: $32.22 - $34.63
Market Cap: $3,261,293,824
Volume: 726,243
Performance Metrics
1 Week: 15.52%
1 Month: 3.31%
3 Months: -24.27%
6 Months: 14.75%
1 Year: 145.6%
YTD: -20.45%
Company Details
Employees: 196
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.